Syner-med (Pp)
Syner-Med (Pharmaceutical Products) Ltd is a UK-based biopharmaceutical company that in-licenses, develops, and commercialises niche medicines and medical devices (urokinase, sodium hyaluronate, citrate lock solutions) addressing unmet clinical needs in vascular access, urology, and urogynaecology, distributed across 12+ countries through a global partner network.
- Company typePrivate
- Founded1994
- HeadquartersPurley, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Syner-med (Pp) does
Syner-Med (Pharmaceutical Products) Ltd is a privately held UK-based biopharmaceutical company founded in 1994 and headquartered in Reigate, Surrey (with a registered office in London). The company specialises in the licensing, clinical development, and commercialisation of medicines and medical devices targeting unmet clinical needs in Vascular Access, Urology, Urogynaecology, Renal, Haematology/Oncology/Critical Care, and Venous Thromboembolic Disease. It operates a sales-led go-to-market selling into Specialty Channel clients — pharmacies, hospitals, NHS and private renal dialysis units, and urology departments — primarily through a global network of in-country distribution partners rather than direct sales infrastructure.
The product portfolio rests on three regulated assets built around the company's urokinase and GAG-layer-replenishment focus. Syner-KINASE® is a urokinase lyophilised powder product dosed at 10,000–500,000 IU, indicated for thrombosed catheters and systemic thromboembolic occlusive disease. Hyacyst® (sodium hyaluronate) is a Class IIa bladder instillation supplied in 40 mg/50 mL and 120 mg/50 mL pre-filled syringes for temporary GAG layer replenishment. D.B.M. C-LOCK (sterile sodium citrate) is a Class IIb catheter lock solution in 30% and 46.7% concentrations for maintaining central venous catheter patency between dialysis sessions. Underlying manufacturing capability includes co-ownership of BioAPI S.A., a dedicated facility producing the urokinase Active Pharmaceutical Ingredient.
Syner-Med monetises primarily through one-time product sales of branded pharmaceuticals and medical devices to institutional buyers, with revenue streams tied to its partner-distributed international footprint covering 12+ countries (UK plus France, Germany, Spain, the Netherlands, Italy, Turkey, and the wider BENELUX region). Pricing is not publicly disclosed; commercial activity is gated through a dedicated Sales and Business Development contact channel and supplemented by direct marketing via ZOHO CRM. Distribution partners include İstem Medikal (since 2010), Théradial (since 2018), Lyomark GmbH and MANA Pharma SL (since 2021), D.B.M. S.r.l. (since 2023), and Eurocept International BV (since 2025). The company holds an active UK ICO data controller registration (Z1290608) and operates an ABPI-compliant disclosure framework, including EU Clinical Trials Register participation.
Syner-med (Pp) firmographics
Firmographics- Name
- Syner-med (Pp)
- Legal name
- Syner Med (Pharmaceutical Products) Limited
- Website
- https://syner-med.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Syner-Med (Pharmaceutical Products) Ltd is a UK-based biopharmaceutical company that in-licenses, develops, and commercialises niche medicines and medical devices (urokinase, sodium hyaluronate, citrate lock solutions) addressing unmet clinical needs in vascular access, urology, and urogynaecology, distributed across 12+ countries through a global partner network.
- Ownership category
- akta.pro rank
Syner-med (Pp) industry classification
Industry- Product category
- Specialty Pharmaceuticals & Medical Devices
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
- akta.pro secondary industry
- Nephrology & Urology Pharmaceuticals (HLAIAAAM)
Keywords
Where Syner-med (Pp) is headquartered
LocationHeadquarters
- HQ city
- Purley
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Syner-med (Pp) business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Products: Sale of branded pharmaceutical products including Syner-KINASE® (urokinase) in multiple dosage strengths, distributed across Great Britain and international markets including France, Germany, Spain, and the Netherlands under associated product names.
- Medical Devices: Sale of branded medical devices including Hyacyst® (sodium hyaluronate) bladder instillation and D.B.M. C-LOCK (sterile sodium citrate) catheter lock solution, distributed through a qualified supply chain to ensure effective and well-tolerated treatments.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | B2B pharmaceutical and medical device sales through partner network |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Syner-med (Pp) product offering
Product offeringCore offering
Syner-Med (Pharmaceutical Products) Ltd is a UK-based biopharmaceutical company that specialises in the licensing, clinical development, and commercialisation of medicines and medical devices targeting unmet clinical needs in Vascular Access, Urology, Urogynaecology, Renal, Haematology/Oncology/Critical Care, and Venous Thromboembolic Disease. The company sells branded specialty pharmaceutical products (urokinase) and medical devices (sodium hyaluronate bladder instillations and sodium citrate catheter lock solutions) through an international partner network serving more than 12 countries.
Product overview
Syner-Med (Pharmaceutical Products) Ltd offers a portfolio of medicines and medical devices focused on unmet clinical needs. The pharmaceutical portfolio includes Syner-KINASE® (urokinase), a thrombolytic agent for treating thrombosed catheters and systemic thromboembolic occlusive disease. The medical device portfolio includes Hyacyst® (sodium hyaluronate), a Class IIa bladder instillation for GAG layer replenishment, and D.B.M. C-LOCK (sterile sodium citrate), a Class IIb catheter lock solution for vascular access maintenance. The company operates in therapy areas of Vascular Access, Urology, Urogynaecology, Renal, Haematology/Oncology/Critical Care, and Venous Thromboembolic Disease, serving patients in more than 12 countries through their global partner network.
Differentiator
Problem solved
Functional benefit
Brands
- Syner-KINASE®: A urokinase medicinal product for the treatment of thrombosed catheters and systemic thromboembolic occlusive disease, available in multiple dosage strengths (10,000, 25,000, 100,000, 250,000, 500,000 IU).
- Hyacyst®
- D.B.M. C-LOCK
Products and services
- Syner-KINASE® (urokinase) A medicinal product containing the protein urokinase derived from human urine, presented as a lyophilised powder in vials for the treatment of thrombosed catheters and systemic thromboembolic occlusive disease. Available in dosages of 10,000, 25,000, 100,000, 250,000, and 500,000 IU. Sold to hospital pharmacies, renal/dialysis units, and clinical teams for adult and paediatric patient use under healthcare professional supervision.
- Hyacyst® (sodium hyaluronate) A Class IIa bladder instillation medical device (sodium hyaluronate) indicated for the temporary replenishment of the glycosaminoglycan (GAG) layer of the bladder. Available in 40mg/50ml and 120mg/50ml pre-filled syringes. Targeted at urology and urogynaecology departments treating patients with bladder conditions including recurrent UTIs and interstitial cystitis-related GAG layer depletion.
- D.B.M. C-LOCK (sterile sodium citrate) A Class IIb catheter lock solution (sterile sodium citrate) for safe vascular access practice to maintain patency of central venous catheters between dialysis sessions with anticoagulant function. Available in 30% and 46.7% concentrations in 3ml pre-filled syringes with luer lock adapters. Targeted at NHS and private renal/dialysis units and vascular access teams.
Companies that use Syner-med (Pp)
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Syner-med (Pp) technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Syner-med (Pp) partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- Eurocept International BVcoreEurocept International BV has been a partner since 2025 and provides the medicine Urokinase Syner-Medica® in the BENELUX region (Belgium, Netherlands, Luxembourg). The partnership is the most recently established distribution relationship and enables access to a new regional market.
- D.B.M. S.r.l.coreD.B.M. S.r.l. has been a partner since 2023 and supplies Syner-Med with the medical device D.B.M. C-LOCK (sterile sodium citrate), a catheter lock solution (Class IIb) indicated for maintaining patency of central venous catheters. The partnership enables distribution of this vascular access device through Syner-Med's commercial network.
- Lyomark GmbHcoreLyomark GmbH has been a partner since 2021 and provides the medicine Syner-KINASE® (urokinase) in Germany. The partnership extends the geographic reach of Syner-Med's flagship pharmaceutical product into the important German pharmaceutical market.
- MANA Pharma SLcoreMANA Pharma SL has been a partner since 2021 and provides the medicine Uroquinasa Syner Medica® in Spain. The partnership enables distribution of the urokinase product under the local brand name in the Spanish pharmaceutical market.
- ThéradialcoreThéradial has been a partner since 2018 and provides the medicine ThéraSolv® in France. The partnership enables Syner-Med to make this pharmaceutical product available in the French market through Théradial's local distribution capabilities.
- İstem Medikalcoreİstem Medikal has been a partner since 2010 and supplies Syner-Med with the medical device Hyacyst® (sodium hyaluronate). İstem Medikal is a Turkish medical company that manufactures and supplies urology and urogynaecology products, enabling Syner-Med to distribute Hyacyst® in the UK and other markets.
- BioAPI S.A.coreBioAPI S.A. is a co-owned manufacturing facility of the Syner-Med Group dedicated to the production of the Active Pharmaceutical Ingredient Urokinase. This co-ownership represents a strategic vertical integration of the supply chain for Syner-Med's key pharmaceutical product, ensuring manufacturing control and supply security for the urokinase active ingredient.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Syner-med (Pp) competitors and assessment
Company assessmentBroad incumbents
- Cook Medical: Privately held medical device manufacturer with overlapping urology and vascular-access product portfolios, comparable in private-company status and specialty-channel distribution approach.
- Coloplast: Global leader in urology and ostomy products, overlapping directly with Syner-Med's Hyacyst® bladder therapy area and providing a reference scale benchmark for medical-device commercialisation in urology.
- B. Braun: Global medical device and pharmaceutical company with a major dialysis and vascular-access franchise, directly comparable to Syner-Med's renal/dialysis catheter lock solution customer base.
- Recordati: European specialty pharmaceutical group with a dedicated urology franchise, providing a comparable but broader reference point for specialty pharma commercial scale and therapeutic-area overlap.
- Teleflex: Large diversified medical device company with a substantial vascular-access portfolio, providing the most direct competitive overlap with Syner-Med's D.B.M. C-LOCK catheter lock solution business.
Direct peers
- EUSA Pharma: Specialty biopharma focused on oncology and rare diseases with similar in-licensing and commercialisation model; both serve niche specialty channels across European markets with limited product counts.
- Tillotts Pharma: European specialty pharmaceutical company focused on gastroenterology and adjacent specialty areas with a comparable mid-sized, partner-driven commercialisation model and similar therapeutic-area niche focus.
- Norgine: European specialty pharmaceutical company with a comparable mid-sized, partner-driven model focused on gastroenterology and specialty hospital channels across European geographies.
- Consilient Health: UK-based specialty pharmaceutical company with a similar mid-market, partner-distributed commercialisation approach across therapeutic niches including women's health and urology-adjacent indications.
Emerging players
- UroGen Pharma: Specialty biopharmaceutical company focused exclusively on urothelial and urology therapies, sharing Syner-Med's niche-urology commercial focus but operating with a development-stage pipeline orientation.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Syner-med (Pp) social profiles
Digital presenceSyner-med (Pp) compliance and trust
Trust signalCompliance1 record
Syner-med (Pp) financial estimates
Financial estimateRevenue estimate
Valuation estimate
Syner-med (Pp) leadership team
Management profileNumber of profiles
Profiles1 record
Syner-med (Pp) subsidiaries and ownership
Company hierarchySubsidiaries1 record
Syner-med (Pp) funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Syner-med (Pp) M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Syner-med (Pp)
What does Syner-med (Pp) do?
Syner-Med (Pharmaceutical Products) Ltd is a UK-based biopharmaceutical company that specialises in the licensing, clinical development, and commercialisation of medicines and medical devices targeting unmet clinical needs in Vascular Access, Urology, Urogynaecology, Renal, Haematology/Oncology/Critical Care, and Venous Thromboembolic Disease. The company sells branded specialty pharmaceutical products (urokinase) and medical devices (sodium hyaluronate bladder instillations and sodium citrate catheter lock solutions) through an international partner network serving more than 12 countries.
Is Syner-med (Pp) a public or private company?
Syner-med (Pp) is a private company. It is classified as unknown and is currently operating.
When was Syner-med (Pp) founded?
Syner-med (Pp) was founded in 1994. It employs 101 to 250 people.
Where is Syner-med (Pp) based?
Syner-med (Pp) is headquartered in Purley, United Kingdom, in the Europe region.
How does Syner-med (Pp) make money?
Two revenue lines are on record. Pharmaceutical Products are the primary driver. The others are medical Devices.
Who are Syner-med (Pp)'s main competitors?
Broad incumbents on record are Cook Medical, Coloplast, B. Braun, Recordati and Teleflex. Direct peers are EUSA Pharma, Tillotts Pharma, Norgine and Consilient Health. UroGen Pharma is listed as an emerging player.
Does Syner-med (Pp) have an API?
No public API is recorded for Syner-med (Pp).
What industry is Syner-med (Pp) in?
Syner-med (Pp)'s product category is Specialty Pharmaceuticals & Medical Devices. Its primary akta.pro industry code is HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals, with a secondary code of HLAIAAAM, Nephrology & Urology Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.